Array Biopharma Inc.

Genentech, Inc.

Intermune, Inc.

Michael Lyon

James F Blake

Bin Wang

Peter J Mohr

Indrani W Gunawardana

Eli M Wallace

Yvan Le Huerou

Mark Joseph Chicarelli

Steven Wade Andrews

Yutong Jiang

Huifen Chen

Adam Wade Cook

Li Ren

David A Moreno

Lewis J Gazzard

Jacob Bradley Schwarz

Timothy S Kercher

Andrew T Metcalf

Scott D Seiwert

Lawrence M Blatt

Kevin W Hunt

Brad Newhouse

April L Kennedy

Robert J Kaus

Jane Schmidt

Pierre Martin

Tony P Tang

Paul Nichols

Weidong Liu

Allen A Thomas

Andreas Schumacher

C Todd Eary

Tarek Sammakia

Bradley Barnett

Leonid Beigelman

Brad Owen Buckman

Kevin Ronald Condroski

John Joseph Gaudino

Rui Xu

John E Robinson

Erik James Hicken

Robert Kirk Delisle

James M Graham

Lisa A De Meese

Pete Mohr

Indrani W Gunwardana

Steve Do

Bradley R Barnett

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrrolopyridines as kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed. 

Compounds of Formula I: in which R, R, R, Rand Rhave the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases. 

Triazolopyridine compounds as PIM kinase inhibitors

The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Peptide inhibitors of hepatitis C virus replication

Growing community of inventors

Boulder, CO, United States of America

Michael Lyon